{"id":121,"date":"2022-09-13T11:51:44","date_gmt":"2022-09-13T11:51:44","guid":{"rendered":"https:\/\/admedsol1stg.wpenginepowered.com\/?page_id=121"},"modified":"2024-02-19T11:23:56","modified_gmt":"2024-02-19T11:23:56","slug":"nomination-committee","status":"publish","type":"page","link":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/","title":{"rendered":"Nomination Committee"},"content":{"rendered":"

[et_pb_section fb_built=”1″ module_class=”ams-angle-header white” _builder_version=”4.22.2″ _module_preset=”default” background_image=”https:\/\/admedsol.com\/wp-content\/uploads\/2023\/06\/Nomination-Comittee-1.jpg” background_size=”custom” background_image_width=”50%” background_position=”center_right” custom_padding_tablet=”6rem||4rem||false|false” custom_padding_phone=”5rem||4rem||false|false” background_last_edited=”on|phone” use_background_color_gradient_tablet=”off” use_background_color_gradient_phone=”on” background_color_gradient_direction_phone=”135deg” background_color_gradient_stops_phone=”#03305d 0%|rgba(11,98,159,0.75) 100%” background_color_gradient_overlays_image_tablet=”on” background_size_tablet=”cover” locked=”off” global_colors_info=”{}” custom_css_before_last_edited=”off|phone”][et_pb_row _builder_version=”4.22.2″ _module_preset=”default” custom_margin=”0rem||3.5rem||false|false” custom_margin_tablet=”||0rem||false|false” custom_margin_phone=”||0rem||false|false” custom_margin_last_edited=”on|tablet” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_code _builder_version=”4.22.2″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Corporate Governance<\/div>\n

<\/p>\n

Nomination Committee<\/div>\n

<\/p>\n

Contact Us <\/i><\/a><\/div>\n

[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|off|off” module_id=”ams-breadcrumb-section” _builder_version=”4.22.2″ _module_preset=”default” background_color=”rgba(255,255,255,0.9)” custom_margin=”-3.5rem||0px||false|false” custom_padding=”1rem||1rem||false|false” custom_padding_tablet=”1rem||1rem||true|false” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.18.1″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_sidebar area=”et_pb_widget_area_1″ module_id=”breadcrumbs” _builder_version=”4.18.1″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][\/et_pb_sidebar][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_code _builder_version=”4.21.0″ _module_preset=”default” custom_margin=”0px||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

Terms of Reference<\/h5>\n

[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

1. Membership<\/h5>\n

1.1. The Committee shall comprise at least three Directors. A majority of the members of the Committee shall be independent Non\u2010Executive Directors.<\/pee>1.2. Only members of the Committee have the right to attend Committee meetings. However, other individuals such as the Chief Executive Officer, the Group HR Director and external advisers may be invited to attend for all or part of any meeting, as and when appropriate.<\/pee> 1.3. Appointments to the Committee are made by the Board on the recommendation of the Nomination Committee and shall for a period of up to three years, which may be extended for up to two additional three year periods, provided the Director still meets the criteria for membership of the Committee.<\/pee> 1.4. The Board shall appoint the Committee Chair, who should be either the Chair of the Board or an independent Non\u2010Executive Director. In the absence of the Committee Chair and\/or an appointed deputy, the remaining members present shall elect one themselves to chair the meeting from those who would qualify under these terms of reference to be appointed to that position by the Board. The Chair of the Board shall not chair the Committee when it is dealing with the matter of succession of the Chair of the Board.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

2. Secretary<\/h5>\n

2.1 The Company Secretary or, their nominee, shall act as secretary of the Committee and will ensure that the Committee receives information and papers in a timely manner to enable full and proper consideration to be given to the issues.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

3. Quorum<\/h5>\n

3.1. The quorum necessary for the transaction of business shall be two, both of whom must be independent Non\u2010Executive Directors.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

4. Frequency of Meetings<\/h5>\n

4.1. The Committee shall meet at least twice a year and otherwise as required.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

5. Notice of Meetings<\/h5>\n

5.1. Meetings of the Committee shall be called by the secretary of the Committee at the request of the Committee Chair or any of its members.<\/pee> 5.2. Unless otherwise agreed, notice of each meeting confirming the venue, time and date, together with an agenda of items to be discussed, shall be forwarded to each member of the Committee, any other person required to attend no later than three working days before the date of the meeting. Supporting papers shall be sent to Committee members and to other attendees, as appropriate, at the same time.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

6. Minutes of Meetings<\/h5>\n

6.1. The secretary shall minute the proceedings and decisions of all Committee meetings, including the names of those present and in attendance.<\/pee> 6.2. Draft minutes of Committee meetings shall be circulated to all members of the Committee. Once approved, minutes should be circulated to all other members of the Board unless, exceptionally, it would be inappropriate to do so.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

7. Engagement with Shareholders<\/h5>\n

7.1. The Committee Chair shall attend the Annual General Meeting to answer any shareholder questions on the Committee\u2019s activities. In addition, the Committee Chair should seek engagement with shareholders on significant matters related to the Committee\u2019s area of responsibility.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

8. Duties<\/h5>\n

The Committee should carry out the duties below for the parent company, major subsidiary undertakings and the Group as a whole, as appropriate.<\/pee>The Committee shall:<\/pee> 8.1 Regularly review the structure, size and composition (including the skills, knowledge, experience and diversity) of the Board and make recommendations to the Board with regard to any changes;<\/pee> 8.2 Ensure plans are in place for orderly succession to Board and senior management positions, and oversee the development of a diverse pipeline for succession, taking into account the challenges and opportunities facing the Company, and the skills and expertise are needed on the Board in the future;<\/pee> 8.3 Keep up-to-date and fully informed about strategic issues and commercial changes affecting the Company and the market in which it operates;<\/pee> 8.4 Be responsible for identifying and nominating for the approval of the Board, candidates to fill Board vacancies as and when they arise;<\/pee> 8.5 Before any appointment is made by the Board, evaluate the balance of skills, knowledge, experience and diversity on the Board and, in light of this evaluation prepare a description of the role and capabilities required for a particular appointment and the time commitment expected. In identifying suitable candidates the Committee shall:<\/pee> 8.5.1 use open advertising or the services of external advisers to facilitate the search;<\/pee> 8.5.2 consider candidates from a wide range of backgrounds; and<\/pee> 8.5.3 consider candidates on merit and against objective criteria, having due regard for the benefits of diversity on the Board and taking care that appointees have enough time available to devote to the position.<\/pee> 8.6 Keep under review the leadership needs of the organisation, both Executive and Non\u2010Executive, with a view to ensuring the continued ability of the organisation to compete effectively in the marketplace;<\/pee> 8.7 Ensure that, on appointment to the Board, Non\u2010Executive Directors receive a formal letter of appointment setting out clearly what is expected from them in terms of time commitment, Committee service and involvement outside of Board meetings;<\/pee> 8.8 Prior to the appointment of a Director, other significant time commitments should be disclosed and any additional future commitments should not be undertaken without prior approval of the Board. The proposed appointee should also be required to disclose any other business interests that may result in a conflict of interest. These must be authorised by the Board prior to appointment and any future business interests that could result in a conflict of interest must not be undertaken without prior authorisation of the Board;<\/pee> 8.9 Review the results of the Board evaluation process that relate to the composition of the Board and succession planning;<\/pee> 8.10 Review annually the time required from Non-Executive Directors. Performance evaluation should be used to assess whether the Non-Executive Directors are spending enough time to fulfil their duties;<\/pee> 8.11 Work and liaise as necessary with other Board committees, ensuring that the interaction between committees and with the Board is reviewed regularly; <\/pee> The Committee shall also make recommendations to the Board concerning:<\/pee> 8.12 any changes needed to the succession planning process if its periodic assessment indicates the desired outcomes have not been achieved;<\/pee> 8.13 suitable candidates to fill Board vacancies and succession planning for existing Directors;<\/pee> 8.14 membership of the Audit and Remuneration Committees, in consultation respectively with the Chair of those committees;<\/pee> 8.15 the re\u2010appointment of any Non\u2010Executive Director at the conclusion of their specified term of office having given due regard to their performance and ability to continue to contribute to the Board in the light of the knowledge, skills and experience required;<\/pee> 8.16 the re\u2010election by shareholders of Directors under the annual re\u2010 election provisions of the 2018 UK Corporate Governance Code or the retirement by rotation\u2019 provisions in the Company\u2019s Articles of Association, having due regard to their performance and ability, and why their contribution is important to the Company\u2019s long-term sustainable success in the light of the knowledge, skills and experience required and the need for progressive refreshing of the Board, taking into account the length of service of individual Directors, the Chair and the Board as a whole;<\/pee> 8.17 the appointment of any Director to Executive or other office; and<\/pee> 8.18 any matters relating to the continuation in office of any Director at any time including the suspension or termination of service of an Executive Director as an employee of the Company subject to the provisions of the law and their service contract.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

9. Reporting Responsibilities<\/h5>\n

9.1. The Committee Chair shall report to the Board after each meeting on the nature and content of its discussion, recommendations and actions to be taken;<\/pee> 9.2. The Committee shall make whatever recommendations to the Board it deems appropriate on any area within its remit where action or improvement is needed, and adequate time should be made available for Board discussion when necessary;<\/pee> 9.3. The Committee shall produce a report to be included in the Company\u2019s Annual Report describing the work of the Committee, including:<\/pee> 9.3.1 the process used in relation to appointments, its approach to succession planning and how both support the development of a diverse pipeline;<\/pee> 9.3.2 how Board evaluation has been conducted, the nature and extent of an external evaluator\u2019s contact with the Board and individual Directors, the outcomes and actions taken, and how it has influenced or will influence Board composition; and<\/pee> 9.3.3 the gender balance of those in the senior management team and their direct reports.<\/pee> 9.4. If an external search consultancy has been engaged, it should be identified in the Annual Report alongside a statement about any other connection it has with the Company or individual Directors.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

10. Other Matters<\/h5>\n

The Committee shall:<\/pee> 10.1. At least annually, review the Committee\u2019s constitution and terms of reference to ensure it is operating at maximum effectiveness and recommend any changes it considers necessary to the Board for approval;<\/pee> 10.2. Have access to sufficient resources in order to carry out its duties, including access to the company secretariat for advice and assistance as required;<\/pee> 10.3. Be provided with appropriate and timely training, both in the form of an induction programme for new members and on an ongoing basis for all members;<\/pee> 10.4. Give due consideration to all relevant laws and regulations, the provisions of the 2018 UK Corporate Governance Code and associated guidance, the requirements of the FCA\u2019s Listing Rules, Prospectus Rules and Disclosure Guidance and Transparency Rules sourcebook and any other applicable rules, as appropriate; and<\/pee> 10.5. Ensure that a periodic evaluation of the Committee\u2019s own performance is carried out.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.21.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n

11. Authority<\/h5>\n

11.1. The Committee is authorised by the Board to obtain, at the Company\u2019s expense, outside legal or other professional advice on any matters within its terms of reference.<\/pee>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

The Committee shall comprise at least three Directors. A majority of the members of the Committee shall be independent Non\u2010Executive Directors.<\/p>\n","protected":false},"author":4,"featured_media":803,"parent":115,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"page_collections":[],"class_list":["post-121","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nNomination Committee - Advanced Medical Solutions<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nomination Committee\" \/>\n<meta property=\"og:description\" content=\"The Committee shall comprise at least three Directors. A majority of the members of the Committee shall be independent Non\u2010Executive Directors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/\" \/>\n<meta property=\"og:site_name\" content=\"Advanced Medical Solutions\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-19T11:23:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admedsol.com\/wp-content\/uploads\/2023\/06\/Nomination-Comittee-1.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/nomination-committee\\\/\",\"url\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/nomination-committee\\\/\",\"name\":\"Nomination Committee - Advanced Medical Solutions\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/nomination-committee\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/nomination-committee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admedsol.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Nomination-Comittee-1.jpg\",\"datePublished\":\"2022-09-13T11:51:44+00:00\",\"dateModified\":\"2024-02-19T11:23:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/nomination-committee\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/nomination-committee\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/nomination-committee\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admedsol.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Nomination-Comittee-1.jpg\",\"contentUrl\":\"https:\\\/\\\/admedsol.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Nomination-Comittee-1.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/nomination-committee\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admedsol.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investor Relations\",\"item\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Corporate Governance\",\"item\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Nomination Committee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/#website\",\"url\":\"https:\\\/\\\/admedsol.com\\\/\",\"name\":\"Advanced Medical Solutions\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admedsol.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/#organization\",\"name\":\"Advanced Medical Solutions\",\"url\":\"https:\\\/\\\/admedsol.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admedsol.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/ams-logo-on-white.webp\",\"contentUrl\":\"https:\\\/\\\/admedsol.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/ams-logo-on-white.webp\",\"width\":1200,\"height\":845,\"caption\":\"Advanced Medical Solutions\"},\"image\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/advanced-medical-solutions\\\/\",\"https:\\\/\\\/uk.linkedin.com\\\/showcase\\\/advanced-medical-solutions-surgical\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/showcase\\\/advanced-medical-solutions-woundcare\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nomination Committee - Advanced Medical Solutions","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/","og_locale":"en_US","og_type":"article","og_title":"Nomination Committee","og_description":"The Committee shall comprise at least three Directors. A majority of the members of the Committee shall be independent Non\u2010Executive Directors.","og_url":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/","og_site_name":"Advanced Medical Solutions","article_modified_time":"2024-02-19T11:23:56+00:00","og_image":[{"url":"https:\/\/admedsol.com\/wp-content\/uploads\/2023\/06\/Nomination-Comittee-1.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/","url":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/","name":"Nomination Committee - Advanced Medical Solutions","isPartOf":{"@id":"https:\/\/admedsol.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/#primaryimage"},"image":{"@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/admedsol.com\/wp-content\/uploads\/2023\/06\/Nomination-Comittee-1.jpg","datePublished":"2022-09-13T11:51:44+00:00","dateModified":"2024-02-19T11:23:56+00:00","breadcrumb":{"@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/#primaryimage","url":"https:\/\/admedsol.com\/wp-content\/uploads\/2023\/06\/Nomination-Comittee-1.jpg","contentUrl":"https:\/\/admedsol.com\/wp-content\/uploads\/2023\/06\/Nomination-Comittee-1.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/nomination-committee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admedsol.com\/"},{"@type":"ListItem","position":2,"name":"Investor Relations","item":"https:\/\/admedsol.com\/investor-relations\/"},{"@type":"ListItem","position":3,"name":"Corporate Governance","item":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/"},{"@type":"ListItem","position":4,"name":"Nomination Committee"}]},{"@type":"WebSite","@id":"https:\/\/admedsol.com\/#website","url":"https:\/\/admedsol.com\/","name":"Advanced Medical Solutions","description":"","publisher":{"@id":"https:\/\/admedsol.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admedsol.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admedsol.com\/#organization","name":"Advanced Medical Solutions","url":"https:\/\/admedsol.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admedsol.com\/#\/schema\/logo\/image\/","url":"https:\/\/admedsol.com\/wp-content\/uploads\/2024\/01\/ams-logo-on-white.webp","contentUrl":"https:\/\/admedsol.com\/wp-content\/uploads\/2024\/01\/ams-logo-on-white.webp","width":1200,"height":845,"caption":"Advanced Medical Solutions"},"image":{"@id":"https:\/\/admedsol.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/advanced-medical-solutions\/","https:\/\/uk.linkedin.com\/showcase\/advanced-medical-solutions-surgical\/","https:\/\/www.linkedin.com\/showcase\/advanced-medical-solutions-woundcare\/"]}]}},"_links":{"self":[{"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/pages\/121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/comments?post=121"}],"version-history":[{"count":0,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/pages\/121\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/pages\/115"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/media\/803"}],"wp:attachment":[{"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/media?parent=121"}],"wp:term":[{"taxonomy":"page_collections","embeddable":true,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/page_collections?post=121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}